Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2004
|
| gptkbp:ATCCode |
A07AA11
|
| gptkbp:bioavailability |
<1% (oral)
|
| gptkbp:brand |
gptkb:Normix
gptkb:Xifaxan |
| gptkbp:CASNumber |
80621-81-4
|
| gptkbp:chemicalFormula |
C43H51N3O11
|
| gptkbp:contraindication |
hypersensitivity to rifaximin
|
| gptkbp:drugClass |
gptkb:antibiotic
rifamycin derivative |
| gptkbp:eliminationHalfLife |
6 hours
|
| gptkbp:genericName |
gptkb:rifaximin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xifaxan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Salix_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
inhibits bacterial RNA synthesis
|
| gptkbp:pregnancyCategory |
C (US)
B (Australia) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
abdominal pain headache |
| gptkbp:usedFor |
gptkb:hepatic_encephalopathy
irritable bowel syndrome with diarrhea traveler's diarrhea |
| gptkbp:bfsParent |
gptkb:Bausch_Health_Companies
gptkb:Valeant_Pharmaceuticals |
| gptkbp:bfsLayer |
6
|